The 17G10.2 monoclonal antibody specifically binds to human Immunoglobulin Like Transcript 7 (ILT7), also known as CD85g. The ILT7 protein is encoded by the LILRA4 (Leukocyte Immunoglobulin Like Receptor subfamily A member 4) gene. ILT7 is a member of immunoglobulin-like transcripts (ILT) or leukocyte immunoglobulin-like receptor (LIR) gene family. ILT7 is selectively expressed on plasmacytoid dendrtic cells (pDC) but not on myeloid dendritic cells or other peripheral blood leukocytes. In response to IL-3, IL-3 receptor complex signaling downregulates ILT7 expression by pDC. ILT7 associates with the FcεRIγ signal adapter protein to form a receptor complex that can signal through activation of an immunoreceptor-based tyrosine activation motif (ITAM)-mediated signaling pathway. Signaling through the ILT7-FcεRIγ receptor complex negatively regulates the innate immune functions of pDC. ILT7 crosslinking inhibits TLR responses by pDC such as the stimulated production of type I interferon and other cytokines. Bone marrow stromal cell antigen 2 (BST2) has been identified as a biological ligand for ILT7.
The antibody was conjugated to BD Horizon™ BUV496 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 496-nm. BD Horizon BUV496 can be excited by the ultraviolet laser (355 nm) and detected with a 515/30 nm filter with a 450LP. Due to the excitation of the acceptor dye by other laser lines, there may be significant spillover into the channel detecting BD Horizon V500 or BV510 (eg, 525/40-nm filter). However, the spillover can be corrected through compensation as with any other dye combination.